BY: Jasper Chan
Mar 18, 2022

(Belantamab mafodotin) GlaxoSmithKline



Available as vial containing 100 mg of belantamab mafodotin powder. After reconstitution, the solution contains 50 mg belantamab mafodotin per mL



As monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy


Drug information including formulation, indication, administration and/or presentation updated, registered or launched in Hong Kong within one year prior to the date written is regarded as new in The Pace.

The information in The Pace is provided as a courtesy service to our readers and is intended for medical professional reference only. Please peruse the latest local prescription information prior to prescription.